share_log

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

Chardan Capital将ProQR Therapeutics升级为收购,宣布目标价为2美元
Benzinga ·  2023/11/08 05:19

Chardan Capital analyst Keay Nakae upgrades ProQR Therapeutics (NASDAQ:PRQR) from Neutral to Buy and announces $2 price target.

Chardan Capital分析师Keay Nakae将ProQR Therapeutics(纳斯达克股票代码:PRQR)从中性上调至买入,并宣布了2美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发